ClinicalTrials.gg
CompletedNCT02402166Updated Jun 8, 2021Results posted

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

A Phase 2 interventional study of SPD489 in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire. Completed at 6 sites in United States. Open to participants aged 4 Years to 5 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
4 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
39th of 51
24 · median 48
Started
2015
with 4 others
Phase 2
5 of 51
1 open now
Registered
40th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 39th largest by enrollment, is one of 5 that started in 2015, is one of 5 in phase 2, and was the 40th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD. Generating such data will provide data on the use of SPD489 in the preschool ADHD population.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder (ADHD)
04

Who can participate

Ages eligible
4 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female aged 4-5 years inclusive at the time of consent. Only recruiting male subjects as of December 2015
  2. Subject's parent or LAR must provide signature of , and there must be documentation of assent (if applicable) by the subject in accordance with the ICH GCP Guideline E6 (1996) and applicable regulations, before completing any study-related procedures.
  3. Subject and parent/LAR are willing and able to comply with all of the testing and requirements defined in the protocol, including oversight of morning dosing. Specifically, the same parent/LAR should be available daily to dispense the dose of product for the study duration.
  4. Subject must meet criteria for a primary diagnosis of ADHD (all subtypes) based on a detailed psychiatric evaluation conducted by a sponsor-approved clinician
  5. Subject has an ADHD-RS-IV Preschool Version total score ≥93rd percentile at the Baseline Visit (Visit 0). For boys, this is a score of ≥32. For girls, this is a score of ≥24.
  6. Subject has a CGI-S score ≥4 at the Baseline Visit (Visit 0).
  7. Subject has a Peabody Picture Vocabulary Test, Fourth Edition standard score of ≥70 at the Screening Visit (Visit -1).
  8. Subject has undergone an adequate course of non-pharmacological treatment based on investigator judgment or the subject has a severe enough condition to consider enrollment without undergoing prior non-pharmacological treatment based on investigator judgment.
  9. Subject has, in the opinion of the investigator, participated in a structured group activity (e.g., preschool, sports, Sunday school) so as to assess symptoms and impairment in a setting outside the home.
  10. Subject has lived with the same parent/LAR for ≥6 months.

Exclusion criteria

Exclusion Criteria:

  1. Subject is required to or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are taking monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
  2. Subject has taken another product or has taken part in a clinical study within 30 days prior to the Screening Visit (Visit -1).
  3. Subject is well controlled on his/her current ADHD medication with acceptable tolerability.
  4. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that, in the investigator's opinion, would prohibit the subject from completing the study or would not be in the best interest of the subject. The additional conditions would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
  5. Subject has failed to fully respond, based on investigator judgment, to a previously administered adequate course of amphetamine therapy.
  6. Subject has a documented allergy, , or intolerance to amphetamine or to any in the investigational product.
  7. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  8. Subject has a blood pressure measurement ≥95th percentile for age, sex, and height at the Screening Visit (Visit -1) or the Baseline Visit (Visit 0).
  9. Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems placing them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  10. Subject has any at the Screening Visit (Visit -1) or the Baseline Visit (Visit 0) or clinically significant laboratory abnormalities at the Screening Visit (Visit -1) based on investigator judgment.
  11. Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone and thyroxine at the Screening Visit (Visit -1). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  12. Subject has a current diagnosis of adjustment disorder, autism, psychosis, or bipolar disorder.
  13. Subject is currently considered at risk for suicide in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded, based on the assessment of the investigator.
  14. Subject has a height ≤5th percentile for age and sex at the Screening Visit (Visit -1).
  15. Subject has a weight ≤5th percentile for age and sex at the Screening Visit (Visit -1).
  16. Subject has a history of seizures (other than infantile febrile seizures) or a current diagnosis of Tourette's disorder.
  17. Subject has a chronic or current tic disorder that is judged by the investigator to be exclusionary.
  18. Subject is taking any medication that is excluded.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Single Arm

    There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.

    Drug: SPD489

Interventions

  • DrugSPD489

    All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)

    Also known as: Lisdexmfetamine dimesylate

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment-emergent if it had a start date on or after, or had a start date before but increased in severity after the first dose of investigational product.

    Time frame: From start of study treatment up to safety follow-up (Week 9)

  2. Change in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire at Week 8 / End of Treatment (ET)

    Children's Sleep Habits Questionnaire is a tool designed to screen the most common sleep problems in children, and consists of 33 items for scoring. The instrument evaluates the child's sleep based on behavior within 8 different subscales: bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night walkings, parasomnias, sleep-disordered breathing, and daytime sleepiness. Each item receives a score from 1 (problem occurs rarely) to 3 (problem usually occurs); therefore, a higher score is the worse outcome. Scale ranges are as follows: bedtime resistance: 6 to 18, sleep onset delay: 1 to 3, sleep duration: 3 to 9, sleep anxiety: 4 to 12, night walkings: 3 to 9, parasomnias: 7 to 21, sleep-disordered breathing: 3 to 9, daytime sleepiness: 8 to 24, and total disturbance (items from all scales): 33 to 99.

    Time frame: Baseline, Week 8/ET

  3. Number of Participants With Suicide Related Behavior Assessed by Columbia-Suicide Severity Rating Scale Questionnaire (C-SSRS)

    The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

    Time frame: Baseline, Week 8/ET

Secondary outcomes

  1. Change From Baseline in Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version Total Score at FoTA (Final on Treatment Assessment)

    The ADHD-RS-IV Preschool Version is an 18-item questionnaire that requires the respondent to rate the frequency of occurrence of ADHD symptoms as defined by Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV-TR) criteria. Each item is scored on a 4-point scale ranging from 0 (never or rarely) to 3 (very often) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17). Data presented here was analysed at Final on-Treatment Assessment (FoTA).

    Time frame: Baseline, FoTA

  2. Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)

    CGI-I was performed to rate the severity of a participant's condition on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse). Data presented here was analysed at Final on-Treatment Assessment (FoTA). Improved is defined as a score of "very much improved" or "much improved".

    Time frame: FoTA

  3. Area Under the Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-last) of SPD489 in Plasma

    AUC 0-last is the area under the concentration-time curve from time zero to the time of the last quantifiable concentration of SPD489 in plasma. Pharmacokinetic (PK) parameters were compared against the study NRP104-201 (NCT00557011) to observe and compare the effects of SPD489.

    Time frame: Visit 7 [Dose Maintenance Phase] at pre-dose, and 1, 2, 3, 4, 6, and 8 h post-dose

07

Results

Posted Oct 25, 2018

Participant flow

The study was conducted at seven sites in the United States between 15 Apr 2015 (first participant first visit) and 30 Jun 2016 (last participant last visit).

Participant flow — Overall Study
MilestoneSPD489
Started24
Completed19
Not completed5
Withdrew: Adverse event2
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment-emergent if it had a start date on or after, or had a start date before but increased in severity after the first dose of investigational product.

Time frame:
From start of study treatment up to safety follow-up (Week 9)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level
ParticipantsSPD489 5 mgSPD489 10 mgSPD489 15 mgSPD489 20 mgSPD489 30 mgSPD489
Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level101176619
PrimaryChange in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire at Week 8 / End of Treatment (ET)

Children's Sleep Habits Questionnaire is a tool designed to screen the most common sleep problems in children, and consists of 33 items for scoring. The instrument evaluates the child's sleep based on behavior within 8 different subscales: bedtime resistance, sleep-onset delay, sleep duration, sleep anxiety, night walkings, parasomnias, sleep-disordered breathing, and daytime sleepiness. Each item receives a score from 1 (problem occurs rarely) to 3 (problem usually occurs); therefore, a higher score is the worse outcome. Scale ranges are as follows: bedtime resistance: 6 to 18, sleep onset delay: 1 to 3, sleep duration: 3 to 9, sleep anxiety: 4 to 12, night walkings: 3 to 9, parasomnias: 7 to 21, sleep-disordered breathing: 3 to 9, daytime sleepiness: 8 to 24, and total disturbance (items from all scales): 33 to 99.

Time frame:
Baseline, Week 8/ET
Reported as:
Mean · Units on a Scale
Change in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire at Week 8 / End of Treatment (ET)
Units on a ScaleSPD489
Baseline : Bedtime resistance9.9 ± 3.58
Week 8/ End of Treatment (ET) : Bedtime resistance9.5 ± 3.26
Baseline : Sleep-onset delay1.9 ± 0.85
Week 8/ ET : Sleep-onset delay1.8 ± 0.92
Baseline : Sleep duration4.5 ± 1.56
Week 8/ET : Sleep duration4.0 ± 1.27
Baseline : Sleep anxiety6.6 ± 2.52
Week 8/ET : Sleep anxiety5.5 ± 1.79
Baseline : Night walkings5.0 ± 2.10
Week 8/ET : Night wakings4.7 ± 2.00
Baseline : Parasomnias9.7 ± 2.03
Week 8/ET : Parasomnias8.5 ± 1.57
Baseline : Sleep-disordered breathing3.3 ± 0.82
Week 8/ET : Sleep-disordered breathing3.2 ± 0.66
Baseline : Daytime sleepiness12.1 ± 3.43
Week 8/ET : Daytime sleepiness10.0 ± 3.51
PrimaryNumber of Participants With Suicide Related Behavior Assessed by Columbia-Suicide Severity Rating Scale Questionnaire (C-SSRS)

The C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

Time frame:
Baseline, Week 8/ET
Reported as:
Count of participants · Participants
Number of Participants With Suicide Related Behavior Assessed by Columbia-Suicide Severity Rating Scale Questionnaire (C-SSRS)
ParticipantsSPD489
Number of Participants With Suicide Related Behavior Assessed by Columbia-Suicide Severity Rating Scale Questionnaire (C-SSRS)1
SecondaryChange From Baseline in Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version Total Score at FoTA (Final on Treatment Assessment)

The ADHD-RS-IV Preschool Version is an 18-item questionnaire that requires the respondent to rate the frequency of occurrence of ADHD symptoms as defined by Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV-TR) criteria. Each item is scored on a 4-point scale ranging from 0 (never or rarely) to 3 (very often) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17). Data presented here was analysed at Final on-Treatment Assessment (FoTA).

Time frame:
Baseline, FoTA
Reported as:
Mean · Units on a Scale
Change From Baseline in Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version Total Score at FoTA (Final on Treatment Assessment)
Units on a ScaleSPD489
Baseline43.6 ± 5.54
FoTA-26.1 ± 14.37
SecondaryNumber of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)

CGI-I was performed to rate the severity of a participant's condition on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse). Data presented here was analysed at Final on-Treatment Assessment (FoTA). Improved is defined as a score of "very much improved" or "much improved".

Time frame:
FoTA
Reported as:
Count of participants · Participants
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)
ParticipantsSPD489
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I)20
SecondaryArea Under the Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-last) of SPD489 in Plasma

AUC 0-last is the area under the concentration-time curve from time zero to the time of the last quantifiable concentration of SPD489 in plasma. Pharmacokinetic (PK) parameters were compared against the study NRP104-201 (NCT00557011) to observe and compare the effects of SPD489.

Time frame:
Visit 7 [Dose Maintenance Phase] at pre-dose, and 1, 2, 3, 4, 6, and 8 h post-dose
Reported as:
Mean · hour*nanogram/millilitre(h*ng/mL)
Area Under the Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-last) of SPD489 in Plasma
hour*nanogram/millilitre(h*ng/mL)SPD489 10 mgSPD489 15 mgSPD489 30 mg
Area Under the Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-last) of SPD489 in Plasma9.8 ± NA15.7 ± 4.159.5 ± 22.0

Adverse events

Collected over From Start of Treatment up to Safety Follow up (Week 9). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489 5mg0/24 (0%)0/24 (0%)6/24 (25%)
SPD489 10mg0/23 (0%)0/23 (0%)7/23 (30.4%)
SPD489 15mg0/18 (0%)0/18 (0%)7/18 (38.9%)
SPD489 20mg0/12 (0%)0/12 (0%)6/12 (50%)
SPD489 30mg0/10 (0%)0/10 (0%)6/10 (60%)
SPD4890/24 (0%)0/24 (0%)15/24 (62.5%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSPD489 5mgSPD489 10mgSPD489 15mgSPD489 20mgSPD489 30mgSPD489
Decreased appetiteMetabolism and nutrition disorders1/241/231/183/122/108/24
InsomniaPsychiatric disorders1/242/230/181/122/104/24
Upper respiratory tract infectionInfections and infestations0/240/233/181/120/104/24
Abdominal pain upperGastrointestinal disorders1/241/230/181/120/103/24
Affect labilityPsychiatric disorders0/241/231/181/120/103/24
IrritabilityPsychiatric disorders1/242/230/180/120/103/24
Weight decreasedInvestigations0/240/232/180/120/102/24
VomitingGastrointestinal disorders0/240/230/180/121/101/24
Gastroenteritis viralInfections and infestations0/241/230/180/121/102/24
AnxietyPsychiatric disorders0/240/230/180/121/101/24

Baseline characteristics

Safety analysis set consisted of all participants who had taken at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(years)SPD489
Mean4.7 ± 0.48
Sex: Female, Male
Sex: Female, Male(Participants)SPD489
Female6
Male18
08

Study locations

6 sites
  • AVIDA
    Newport Beach, California 92660, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Center For Psychiatry and Behavioral Medicine In
    Las Vegas, Nevada 89128, United States
  • Duke Child and Family Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Houston Clinical Trials, LLC
    Houston, Texas 77098, United States
09

References and documents

Publications

  • Childress AC, Findling RL, Wu J, Kollins SH, Wang Y, Martin P, Robertson B. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2020 Apr;30(3):128-136. doi: 10.1089/cap.2019.0117. Epub 2020 Feb 11. PubMed 32233956 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Jun 2016, 14 months.

Results were first posted in Oct 2018, 2 years 3 months after primary completion.

Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2015
First posted
Mar 30, 2015
StartActual
Apr 15, 2015
Primary completionActual
Jun 30, 2016
CompletionActual
Jun 30, 2016
Results first posted
Oct 25, 2018
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02402166
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 30, 2015
Start date
Apr 15, 2015
Primary completion
Jun 30, 2016
Completion
Jun 30, 2016
Results posted
Oct 25, 2018
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion